Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer

Lin Yang, Jin wan Wang, Yan Sun, Yun zhong Zhu, Xia qing Liu, Wei lian Li, Li jun Di, Pei wen Li, You liang Wang, Shu ping Song, Chen Yao, Li fen You

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

OBJECTIVE: To investigate the response rate (RR), time to tumor progression (TTP), quality of life (QOL) and adverse reaction in the treatment of pretreated advanced non-small cell lung cancer (NSCLC) using escalated doses of rh-endostatin (YH-16), and to determine the optimal dose for clinical application. METHODS: In this phase II randomized, controlled, multicenter trial, the patients were randomly divided into two groups to receive daily 3 hours intravenous infusion of either 7.5 mg x m(-2) or 15 mg/m(2) YH-16 for 28 days. RESULTS: Totally, 68 patients were entered and 60 patients were evaluable. There were no differences in RR (3.0% in both groups, P > 0.05), median TTP (ITT: 60 days versus 71 days, P > 0.05), QOL and incidence rate of adverse reactions (48.6% versus 38.7%, P > 0.05). No significant unexpected adverse events were observed. CONCLUSION: Rh-endostatin may have anti-tumor activity with high clinical benefit rate and is well tolerated in pretreated advanced NSCLC patients. The dose of 7.5 mg x (m(2))(-1) x d(-1) is clinically recommended.

Original languageEnglish
Pages (from-to)138-141
Number of pages4
JournalZhonghua zhong liu za zhi [Chinese journal of oncology]
Volume28
Issue number2
StatePublished - Feb 2006

Fingerprint

Dive into the research topics of 'Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this